Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

  • 268 views
  • 26 Mar, 2021
  • 16 locations
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

  • 1936 views
  • 04 Aug, 2021
  • 15 locations
The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

  • 0 views
  • 17 Apr, 2021
  • 3 locations
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma

chimeric antigen receptor) (DLBCL NOS [de novo or tFL], follicular lymphoma Grade 3B [FL3B], high grade B-cell Lymphoma [HGBL] and primary central nervous system lymphoma [PCNSL]).

high dose chemotherapy
diffuse large b-cell lymphoma
rituximab
gilbert's syndrome
hodgkin's disease
  • 191 views
  • 25 Jun, 2021
  • 29 locations
GEN3013 Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of epcoritamab GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH) and an expansion part phase 2a.

anti-cd20 monoclonal antibody
ct scan
combination chemotherapy
diffuse large b-cell lymphoma
rituximab
  • 316 views
  • 04 Aug, 2021
  • 100 locations
R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)

with High-Grade B-cell Lymphoma Double-hit and High-Grade B-cell Lymphoma Not Otherwise Specified.

b-cell lymphoma
cell transplantation
diffuse large b-cell lymphoma
  • 34 views
  • 22 Jan, 2021
  • 1 location
Testing the Addition of a New Anti-cancer Drug Venetoclax to Usual Chemotherapy for High Grade B-cell Lymphomas

This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of

doxorubicin
etoposide
vincristine
prednisone
rituximab
  • 168 views
  • 04 Aug, 2021
  • 537 locations
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

thrombocytopenia
leukemia
bone marrow transplant
cancer
bone marrow procedure
  • 38 views
  • 26 Jan, 2021
  • 11 locations
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma

This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double or triple hit lymphoma. Polatuzumab vedotin is a monoclonal antibody that works by binding with cancer cells and releasing another chemotherapy drug, called monomethyl auristatin E, into the cell causing …

doxorubicin
prednisolone
prednisone
rituximab
monoclonal antibodies
  • 0 views
  • 15 Apr, 2021
  • 1 location
A Multicentre Parallel Arm Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

vedotin-RCHP for younger patients with higher-risk Diffuse Large B-cell Lymphoma or High Grade B-Cell Lymphoma.

  • 0 views
  • 02 Aug, 2021
  • 1 location